{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:15:10Z","timestamp":1754162110623,"version":"3.41.2"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Early revascularization, invasive hemodynamic profiling, and initiation of temporary mechanical circulatory support (MCS) have all become routine components of cardiogenic shock (CS) management. Despite this evolution in clinical practice, patient selection and timing of treatment initiation remain a significant barrier to achieving sustained improvement in CS outcomes. Recent efforts to standardize CS management, through the development of treatment algorithms, have relied heavily on surrogate endpoints to drive therapeutic decisions. The present review aims to provide an overview of the basis of evidence for those surrogate endpoints commonly employed in clinical trials and CS management algorithms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent publications from both observational and randomized cohorts have demonstrated the utility of surrogate endpoints in risk stratifying patients with CS. In particular, invasive hemodynamics using pulmonary artery catheters to guide initiation and weaning of MCS, biochemical markers that portend imminent end-organ failure, and clinical risk scores that combine multiple hemodynamic and laboratory parameters have demonstrated an ability to prognosticate outcomes in patients with CS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Although further validation is necessary, multiple clinical, hemodynamic, and biochemical markers have demonstrated utility as surrogate endpoints in CS, and will undoubtedly assist physicians in clinical decision-making.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcc.0000000000000963","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T05:00:08Z","timestamp":1656306008000},"page":"442-452","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes in cardiogenic shock: the role of surrogate endpoints"],"prefix":"10.1097","volume":"28","author":[{"given":"Leah B.","family":"Kosyakovsky","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Marbach","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center"},{"name":"The Cardiogenic Shock Working Group, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khoa","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Oregon Health Sciences University Knight Cardiovascular Center, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srini","family":"Mukundan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Oregon Health Sciences University Knight Cardiovascular Center, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haval","family":"Chweich","sequence":"additional","affiliation":[{"name":"Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navin K.","family":"Kapur","sequence":"additional","affiliation":[{"name":"The Cardiogenic Shock Working Group, Tufts Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiovascular Medicine, Oregon Health Sciences University Knight Cardiovascular Center, Portland, Oregon"},{"name":"Department of Medicine"},{"name":"The Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jacc.2018.12.084","article-title":"Standardized team-based care for cardiogenic shock","volume":"73","author":"Tehrani","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jchf.2020.09.005","article-title":"A standardized and comprehensive approach to the management of cardiogenic shock","volume":"8","author":"Tehrani","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R3-20250729","first-page":"1173","article-title":"Improved outcomes associated with the use of shock protocols: updates from the national cardiogenic shock initiative","volume":"93","author":"Basir","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"R4-20250729","first-page":"e232","article-title":"Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association","volume":"136","author":"van Diepen Sean","year":"2017","journal-title":"Circulation"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"(1)","key":"R6-20250729","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Medicine"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/jama.294.13.1625","article-title":"Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization EffectivenessThe ESCAPE Trial","volume":"294","year":"2005","journal-title":"JAMA"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000448110","article-title":"Impact of pulmonary artery catheter use on short- and long-term mortality in patients with cardiogenic shock","volume":"136","author":"Rossello","year":"2017","journal-title":"Cardiology"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ahj.2018.03.024","article-title":"Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device","volume":"202","author":"O\u2019Neill","year":"2018","journal-title":"Am Heart J"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jchf.2020.08.012","article-title":"Complete hemodynamic profiling with pulmonary artery catheters in cardiogenic shock is associated with lower in-hospital mortality","volume":"8","author":"Garan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s12630-021-02083-2","article-title":"Pulmonary artery catheterization in patients with cardiogenic shock: a systematic review and meta-analysis","volume":"68","author":"Chow","year":"2021","journal-title":"Can J Anaesth"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ejhf.260","article-title":"Clinical picture and risk prediction of short-term mortality in cardiogenic shock","volume":"17","author":"Harjola","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R14-20250729","first-page":"33","article-title":"Cardiogenic shock due to predominantly right ventricular failure complicating acute myocardial infarction","volume":"10","author":"Josiassen","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"e007099","DOI":"10.1161\/CIRCHEARTFAILURE.120.007099","article-title":"Invasive hemodynamic assessment and classification of in-hospital mortality risk among patients with cardiogenic shock","volume":"13","author":"Thayer","year":"2020","journal-title":"Circ Heart Fail"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cardfail.2021.07.013","article-title":"Right ventricular dysfunction is common and identifies patients at risk of dying in cardiogenic shock","volume":"27","author":"Jain","year":"2021","journal-title":"J Card Fail"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cardfail.2017.10.009","article-title":"Right ventricular dysfunction in acute myocardial infarction complicated by cardiogenic shock: a hemodynamic analysis of the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Trial and Registry","volume":"24","author":"Lala","year":"2018","journal-title":"J Card Fail"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/eurjhf\/hfp204","article-title":"Right ventricular dysfunction is an independent predictor for mortality in ST-elevation myocardial infarction patients presenting with cardiogenic shock on admission","volume":"12","author":"Engstr\u00f6m","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacc.2004.03.060","article-title":"Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry","volume":"44","author":"Fincke","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ahj.2006.11.014","article-title":"Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac disease","volume":"153","author":"Mendoza","year":"2007","journal-title":"Am Heart J"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/cc8114","article-title":"Hemodynamic variables and mortality in cardiogenic shock: a retrospective cohort study","volume":"13","author":"Torgersen","year":"2009","journal-title":"Crit Care"},{"key":"R22-20250729","first-page":"712","article-title":"The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial","volume":"10","author":"Parlow","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"(3)","key":"R23-20250729","article-title":"Vasopressors independently associated with mortality in acute myocardial infarction and cardiogenic shock","volume":"99","author":"Basir","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jcin.2020.06.037","article-title":"Arterial lactate in cardiogenic shock: prognostic value of clearance versus single values","volume":"13","author":"Fuernau","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.cardfail.2021.08.012","article-title":"Lactate clearance is associated with improved survival in cardiogenic shock: a systematic review and meta-analysis of prognostic factor studies","volume":"27","author":"Marbach","year":"2021","journal-title":"J Card Fail"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"e023322","DOI":"10.1161\/JAHA.121.023322","article-title":"Lactate clearance as a surrogate for mortality in cardiogenic shock: Insights from the DOREMI Trial","volume":"11","author":"Marbach","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijcard.2016.10.033","article-title":"The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock \u2013 results from the CardShock Study","volume":"226","author":"Kataja","year":"2017","journal-title":"Int J Cardiol"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.jacc.2017.02.027","article-title":"Risk stratification for patients in cardiogenic shock after acute myocardial infarction","volume":"69","author":"P\u00f6ss","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/eurheartj\/ehab110","article-title":"The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction","volume":"42","author":"Ceglarek","year":"2021","journal-title":"Eur Heart J"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1093\/eurheartj\/ehz294","article-title":"Protein-based cardiogenic shock patient classifier","volume":"40","author":"Rueda","year":"2019","journal-title":"Eur Heart J"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jacc.2022.01.018","article-title":"SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies","volume":"79","author":"Naidu","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2019.10.012","article-title":"Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies postdischarge mortality risk in cardiac intensive care unit patients","volume":"219","author":"Jentzer","year":"2020","journal-title":"Am Heart J"},{"key":"R33-20250729","first-page":"1137","article-title":"SCAI shock classification in acute myocardial infarction: Insights from the National Cardiogenic Shock Initiative","volume":"96","author":"Hanson","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"R34-20250729","first-page":"E213","article-title":"Application of the SCAI classification in a cohort of patients with cardiogenic shock","volume":"96","author":"Schrage","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.jacc.2019.07.077","article-title":"Cardiogenic shock classification to predict mortality in the cardiac intensive care unit","volume":"74","author":"Jentzer","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"e007678","DOI":"10.1161\/CIRCHEARTFAILURE.120.007678","article-title":"Defining shock and preshock for mortality risk stratification in cardiac intensive care unit patients","volume":"14","author":"Jentzer Jacob","year":"2021","journal-title":"Circ Heart Fail"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.amjcard.2016.11.037","article-title":"Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock","volume":"119","author":"Basir","year":"2017","journal-title":"Am J Cardiol"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2019.04.019","article-title":"Rationale and design of DanGer shock: Danish-German cardiogenic shock trial","volume":"214","author":"Udesen","year":"2019","journal-title":"Am Heart J"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"e1227","DOI":"10.4244\/EIJ-D-20-01076","article-title":"Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the randomised, multicentre, open-label EURO SHOCK trial","volume":"16","author":"Banning","year":"2021","journal-title":"EuroIntervention"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.xjon.2021.07.024","article-title":"Proposal for a trial of early left ventricular venting during venoarterial extracorporeal membrane oxygenation for cardiogenic shock","volume":"8","author":"Ibrahim","year":"2021","journal-title":"JTCVS Open"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"e020085","DOI":"10.1161\/JAHA.120.020085","article-title":"Phenotyping Cardiogenic Shock","volume":"10","author":"Zweck","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"e006956","DOI":"10.1161\/CIRCOUTCOMES.120.006956","article-title":"Systemic inflammatory response syndrome is associated with increased mortality across the spectrum of shock severity in cardiac intensive care patients","volume":"13","author":"Jentzer","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R43-20250729","first-page":"e815","article-title":"Invasive management of acute myocardial infarction complicated by cardiogenic shock: a scientific statement from the American Heart Association","volume":"143","author":"Henry Timothy","year":"2021","journal-title":"Circulation"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:05:57Z","timestamp":1753819557000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000000963","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"type":"print","value":"1070-5295"},{"type":"electronic","value":"1531-7072"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}